Today, lymphoma represents one of the most complex and diverse malignancies in routine clinical practice and huge advances have been made in the pathological classification and treatment of this family of diseases. Progress in treatment means that long-term survival is now an achievable goal for many, although a proportion of patients remain incurable. Developments in both conventional chemotherapy as well as biotechnological advances have opened new therapeutic approaches, many of which have already reached the clinic.